ARVN [NASD]
Arvinas, Inc.
Index- P/E- EPS (ttm)-4.17 Insider Own2.10% Shs Outstand53.00M Perf Week-3.25%
Market Cap2.20B Forward P/E- EPS next Y-5.28 Insider Trans-30.84% Shs Float47.04M Perf Month-23.20%
Income-213.40M PEG- EPS next Q-1.03 Inst Own89.60% Short Float9.23% Perf Quarter-33.36%
Sales65.40M P/S33.57 EPS this Y-26.60% Inst Trans4.57% Short Ratio8.88 Perf Half Y-44.85%
Book/sh13.65 P/B3.16 EPS next Y-22.20% ROA-16.10% Target Price106.33 Perf Year-40.62%
Cash/sh28.10 P/C1.54 EPS next 5Y- ROE-29.40% 52W Range37.41 - 108.46 Perf YTD-47.42%
Dividend- P/FCF4.10 EPS past 5Y-57.30% ROI- 52W High-60.18% Beta2.11
Dividend %- Quick Ratio6.10 Sales past 5Y47.60% Gross Margin- 52W Low15.45% ATR3.64
Employees280 Current Ratio6.10 Sales Q/Q340.00% Oper. Margin- RSI (14)40.10 Volatility6.81% 8.31%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.00% Profit Margin- Rel Volume0.95 Prev Close41.30
ShortableYes LT Debt/Eq0.00 EarningsFeb 28 BMO Payout- Avg Volume489.20K Price43.19
Recom1.80 SMA20-4.50% SMA50-25.11% SMA200-41.24% Volume463,912 Change4.58%
May-09-22Downgrade Wedbush Outperform → Neutral
Apr-28-22Initiated Credit Suisse Outperform $104
Apr-06-22Initiated Morgan Stanley Equal-Weight $65
Feb-11-22Resumed BMO Capital Markets Outperform $125
Feb-10-22Initiated Wells Fargo Overweight $98
Jan-19-22Initiated Goldman Buy $157
Dec-07-21Initiated Cowen Outperform
Oct-14-21Initiated SVB Leerink Outperform $115
Sep-30-21Initiated Stifel Buy $115
Sep-09-21Initiated BofA Securities Buy $110
May-21-21Initiated UBS Buy $123
Apr-21-21Initiated Truist Buy $150
Mar-31-21Initiated BMO Capital Markets Outperform $101
Dec-14-20Upgrade Oppenheimer Perform → Outperform
Jun-01-20Upgrade Citigroup Neutral → Buy $45
May-12-20Initiated Oppenheimer Perform
Dec-19-19Initiated H.C. Wainwright Buy $50
Nov-25-19Initiated Guggenheim Buy $50
Oct-24-19Upgrade Goldman Neutral → Buy $23 → $38
Sep-25-19Initiated Wedbush Outperform $38
May-10-22 08:26AM  
May-09-22 10:00AM  
May-05-22 08:15AM  
07:00AM  
May-03-22 07:00AM  
Apr-26-22 03:01PM  
Mar-04-22 07:00AM  
Mar-02-22 11:22AM  
Feb-28-22 08:25AM  
07:00AM  
Feb-25-22 10:14AM  
Feb-24-22 10:15AM  
Feb-17-22 08:00AM  
04:40AM  
Feb-15-22 12:50PM  
Feb-14-22 06:04PM  
Feb-03-22 04:30PM  
Jan-31-22 09:04AM  
Jan-06-22 05:38PM  
Dec-13-21 04:38PM  
Dec-12-21 11:00AM  
Dec-10-21 10:40AM  
08:10AM  
Nov-19-21 09:55AM  
04:24AM  
Nov-18-21 10:28AM  
Nov-16-21 10:24AM  
08:50AM  
Nov-10-21 11:35AM  
07:00AM  
Nov-03-21 08:25AM  
07:00AM  
Oct-20-21 06:05PM  
04:02PM  
Sep-01-21 07:00AM  
Aug-15-21 03:04AM  
Aug-09-21 09:47AM  
09:16AM  
09:16AM  
Aug-05-21 10:25AM  
07:00AM  
Aug-01-21 10:54AM  
Jul-29-21 08:50AM  
Jul-27-21 03:02PM  
12:00PM  
Jul-26-21 03:53AM  
Jul-23-21 11:06AM  
Jul-22-21 03:21PM  
08:06AM  
07:00AM  
06:32AM  
Jul-13-21 12:32PM  
Jul-08-21 02:03AM  
Jun-07-21 05:19PM  
Jun-03-21 07:00AM  
May-21-21 04:03PM  
May-20-21 04:30PM  
May-09-21 03:10AM  
May-04-21 02:52PM  
08:45AM  
07:00AM  
Apr-22-21 05:44PM  
Apr-19-21 01:38AM  
Apr-12-21 02:28PM  
Apr-05-21 04:30PM  
Mar-10-21 04:30PM  
Mar-01-21 08:15AM  
07:59AM  
07:00AM  
Feb-18-21 12:01AM  
Feb-08-21 04:30PM  
Dec-28-20 04:30PM  
Dec-23-20 04:40PM  
Dec-16-20 01:37PM  
Dec-15-20 08:35PM  
07:48PM  
09:48AM  
09:17AM  
Dec-14-20 04:37PM  
04:06PM  
01:50PM  
09:48AM  
07:00AM  
Dec-11-20 04:15PM  
Nov-25-20 07:00AM  
Nov-16-20 09:21AM  
Nov-07-20 07:43AM  
Nov-05-20 07:00AM  
05:52AM  
Oct-14-20 07:00AM  
Oct-06-20 05:17PM  
Sep-15-20 11:42AM  
Sep-04-20 07:00AM  
Aug-07-20 07:00AM  
Aug-04-20 09:05AM  
07:00AM  
Jul-30-20 08:45AM  
Jul-27-20 12:31PM  
Jul-20-20 12:15PM  
Jun-29-20 04:30PM  
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrison BriggsDirectorApr 14Option Exercise16.0016,188259,00840,936Apr 18 09:00 PM
Morrison BriggsDirectorApr 14Sale66.4420,9601,392,61619,976Apr 18 09:00 PM
Cassidy Sean AChief Financial OfficerMar 11Option Exercise16.0015,000240,000176,447Mar 15 08:00 PM
Cassidy Sean AChief Financial OfficerMar 11Sale70.0015,0001,050,000161,447Mar 15 08:00 PM
Houston John GPresident and CEOMar 04Sale63.946,024385,175843,820Mar 04 09:00 PM
Cassidy Sean AChief Financial OfficerMar 04Sale63.941,593101,856161,447Mar 04 09:00 PM
Taylor IanChief Scientific OfficerMar 04Sale63.9486955,56483,962Mar 04 09:00 PM
Taylor IanChief Scientific OfficerMar 01Option Exercise16.003,50056,00082,145Mar 03 09:00 PM
Taylor IanChief Scientific OfficerFeb 15Option Exercise19.3620,000387,20098,645Feb 17 09:00 PM
Taylor IanChief Scientific OfficerFeb 15Sale73.0220,0001,460,31678,645Feb 17 09:00 PM
Morrison BriggsDirectorJan 14Option Exercise16.0016,188259,00845,708Jan 19 09:00 PM
Morrison BriggsDirectorJan 14Sale65.5520,9601,374,02124,748Jan 19 09:00 PM
Peck RonaldChief Medical OfficerDec 30Option Exercise41.5320,000830,60025,402Jan 04 09:00 PM
Peck RonaldChief Medical OfficerDec 30Sale80.6120,0001,612,2645,402Jan 04 09:00 PM
Cassidy Sean AChief Financial OfficerDec 17Option Exercise16.0015,000240,000173,249Dec 21 09:15 PM
Cassidy Sean AChief Financial OfficerDec 17Sale70.0015,0001,050,000158,249Dec 21 09:15 PM
Ratcliffe LiamDirectorDec 16Sale69.3685,7055,944,418185,686Dec 16 09:30 PM
Ratcliffe LiamDirectorDec 15Sale66.81113,5367,584,964271,391Dec 16 09:30 PM
Ratcliffe LiamDirectorDec 14Sale65.86156,46410,303,999384,927Dec 16 09:30 PM
Taylor IanChief Scientific OfficerNov 15Option Exercise17.3120,000346,18898,645Nov 17 08:30 PM
Taylor IanChief Scientific OfficerNov 15Sale84.0420,0001,680,74678,645Nov 17 08:30 PM
Ratcliffe LiamDirectorNov 15Sale84.8721,2841,806,469541,391Nov 15 09:45 PM
Ratcliffe LiamDirectorNov 12Sale84.9439,8693,386,461562,675Nov 15 09:45 PM
Ratcliffe LiamDirectorNov 11Sale86.2359,7995,156,393602,544Nov 15 09:45 PM
Ratcliffe LiamDirectorNov 10Sale88.2013,3581,178,188662,343Nov 15 09:45 PM
Ratcliffe LiamDirectorNov 09Sale91.9733,0083,035,861675,701Nov 09 09:47 PM
Ratcliffe LiamDirectorNov 08Sale94.4581,0547,655,882708,709Nov 09 09:47 PM
Ratcliffe LiamDirectorNov 05Option Exercise29.5618,423544,53124,923Nov 09 09:47 PM
Ratcliffe LiamDirectorNov 05Sale91.8433,0943,039,319789,763Nov 09 09:47 PM
Ratcliffe LiamDirectorNov 05Sale91.3024,9232,275,3620Nov 09 09:47 PM
Houston John GPresident and CEONov 01Option Exercise16.0040,000640,000872,333Nov 03 09:46 PM
Houston John GPresident and CEONov 01Sale88.1440,0003,525,724832,333Nov 03 09:46 PM
SHANNON TIMOTHY MDirectorSep 07Sale89.0936,4113,243,7961,653,128Sep 27 02:22 PM
SHANNON TIMOTHY MDirectorSep 03Sale85.5332,3872,770,1461,689,539Sep 27 02:22 PM
Houston John GPresident and CEOSep 02Option Exercise16.004,69075,040832,333Sep 07 08:00 PM
SHANNON TIMOTHY MDirectorSep 02Sale85.8351,7654,443,1161,721,926Sep 27 02:19 PM
SHANNON TIMOTHY MDirectorSep 01Sale87.0579,4376,915,2211,773,691Sep 27 02:19 PM
SHANNON TIMOTHY MDirectorAug 31Sale85.5659,3555,078,1511,853,128Sep 27 02:19 PM
SHANNON TIMOTHY MDirectorAug 30Sale86.0758,8385,064,4581,912,483Sep 27 02:18 PM
SHANNON TIMOTHY MDirectorAug 27Sale85.4245,0263,845,9511,971,321Sep 27 02:18 PM
SHANNON TIMOTHY MDirectorAug 26Sale85.1211,712996,9702,016,347Sep 27 02:18 PM
Margus Bradley AlbertDirectorAug 26Sale85.039,940845,1682,000Aug 27 04:29 PM
Margus Bradley AlbertDirectorAug 25Sale85.0020,0001,700,00011,940Aug 27 04:29 PM
SHANNON TIMOTHY MDirectorAug 25Sale85.0314,2671,213,1442,028,059Sep 27 02:16 PM
SHANNON TIMOTHY MDirectorAug 24Sale87.029,203800,8182,042,326Sep 27 02:16 PM
SHANNON TIMOTHY MDirectorAug 23Sale88.011,599140,7282,051,529Sep 27 02:16 PM
Taylor IanChief Scientific OfficerAug 16Option Exercise16.0020,000320,00098,645Aug 18 09:05 PM
Taylor IanChief Scientific OfficerAug 16Sale87.3020,0001,745,91778,645Aug 18 09:05 PM
Margus Bradley AlbertDirectorAug 13Sale90.035,828524,69531,940Aug 13 09:00 PM
Peck RonaldChief Medical OfficerAug 12Sale90.541,363123,3995,402Aug 16 09:00 PM
Margus Bradley AlbertDirectorAug 11Sale90.035,000450,15037,768Aug 13 09:00 PM
Houston John GPresident and CEOAug 02Option Exercise16.0045,922734,752873,565Aug 04 08:05 PM
Houston John GPresident and CEOAug 02Sale97.8345,9224,492,415827,643Aug 04 08:05 PM
Cassidy Sean AChief Financial OfficerJul 28Option Exercise16.0017,242275,872175,491Jul 30 08:05 PM
Cassidy Sean AChief Financial OfficerJul 28Sale100.0017,2421,724,200158,249Jul 30 08:05 PM
Peck RonaldChief Medical OfficerJun 30Option Exercise47.3820,000947,60022,754Jul 02 08:00 PM
Peck RonaldChief Medical OfficerJun 30Sale76.6920,0001,533,8002,754Jul 02 08:00 PM
Houston John GPresident and CEOJun 10Option Exercise16.0043,886702,176871,529Jun 11 08:07 PM
Houston John GPresident and CEOJun 10Sale81.4943,8863,576,263827,643Jun 11 08:07 PM
Houston John GPresident and CEOJun 09Option Exercise16.0070011,200828,343Jun 11 08:07 PM
Houston John GPresident and CEOJun 09Sale80.1570056,104827,643Jun 11 08:07 PM